When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals details the research of Richard A. Young of the Whitehead Institute and his discovery of super-enhancers, large groups of transcriptional enhancers that drive expression…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals elaborates on the breakthrough discovery of super-enhancers, large groups of transcriptional enhancers that drive expression of genes that define cell identity. By identifying…
By Will Boggs, MD NEW YORK (Reuters Health) – Median survival of patients with metastatic gastric cancer has not improved, despite increased use of chemotherapy, researchers from The…
HIV infection attacks the immune system. In many parts of Africa, patients with HIV infection, also have vitamin deficiencies. A new study examined whether giving a multivitamin and…
By Will Boggs, MD NEW YORK (Reuters Health) – Improved survival among women with stage I or II endometrial cancer who undergo radiotherapy and lymphadenectomy may be attributable…
By Will Boggs, MD NEW YORK (Reuters Health) – Some patients with gastrointestinal stromal tumors (GIST) may benefit from resuming imatinib even after a previous failure of imatinib…
NEW YORK (Reuters Health) – Breast cancer metastases in a given patient often have a different receptor status, a new study demonstrates. “Different metastases within the same patient…
NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare…
NEW YORK (Reuters Health) – A Dutch population-based study has shown that, while mucinous colorectal cancer is thought to carry a poor prognosis, it actually responds as well…
NEW YORK (Reuters Health) – Ten-year follow-up data from two UK trials confirm that a lower total dose of radiotherapy delivered in fewer, larger fractions is at least…
